<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042366</url>
  </required_header>
  <id_info>
    <org_study_id>UPCI 01-171</org_study_id>
    <secondary_id>5P01CA073743</secondary_id>
    <nct_id>NCT01042366</nct_id>
  </id_info>
  <brief_title>Dendritic Cells (DC) Vaccine for Metastatic Melanoma</brief_title>
  <official_title>Randomized Phase II Evaluation of Immunization Against Tumor Cells in Subjects With Metastatic Melanoma Using Autologous Mature Dendritic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Kirkwood</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine what effect using an experimental tumor vaccine (a
      substance or group of substances meant to cause the immune system to respond to a tumor) made
      using patients' own tumor cells and blood cells will have on their melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Historically, metastatic melanoma has been associated with a poor prognosis. Recently,
      numerous immunotherapeutic agents, particularly checkpoint inhibitors, have moved to the
      forefront of therapy. Checkpoint inhibitors such as ipilimumab, pembrolizumab, and nivolumab
      have revolutionized the treatment of melanoma. Despite this, not all patients respond to
      checkpoint inhibitors, and even patients who initially respond to checkpoint inhibitor
      therapy often later relapse (median response duration of 2 years); complete responses remain
      uncommon. Thus, more effective immunotherapies are clearly needed.

      The concept of administering dendritic cell (DC)-based vaccines to prompt an immune response
      against tumor cells has shown promise in the treatment of advanced cancers. Sipuleucel-T, now
      FDA-approved for the treatment of advanced prostate cancer, is one such vaccine that consists
      of autologous antigen-presenting cell (APC) activated ex vivo by a fusion protein consisting
      of the antigen prostatic acid phosphatase (PAP) and granulocyte-macrophage colony stimulating
      factor (GM-CSF). Although response rates to Sipuleucel-T are low, recent studies suggest that
      DC vaccines have the potential to improve survival by increasing the breadth and diversity of
      melanoma-specific T cells.

      It is known that the method of antigen (Ag) delivery is important for the success of DC
      vaccines, but it remains unclear which method is most effective in producing antitumor
      responses. Approaches tested clinically include pulsing with HLA-restricted defined peptide
      Ags, loading with purified proteins, transfecting with mRNA, engineering with Ag-encoding
      viral vectors, and using autologous tumor cells or allogeneic cell lines directly as sources
      of Ag. Efficacy can be measured in vivo using surrogate endpoints, such as development of
      tumor-specific delayed-type hypersensitivity (DTH) reactions. Prolonged survival of
      vaccinated melanoma patients has been reported to correlate with induction of positive DTH
      tests. Antitumor activity may also be assessed by ELISpot analysis of the frequency of
      tumor-Ag specific IFNÎ³-producing T cells. To assess the quality of the DC vaccines, surrogate
      markers of DC function including maturation markers, co-stimulatory molecule expression, and
      IL12p70 production, a critical cytokine in antitumor response, can be measured
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed to accrual in March 2009 for slow accrual.
  </why_stopped>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Delayed Type Hypersensitivity (DTH) Response</measure>
    <time_frame>12 mo</time_frame>
    <description>Delayed type hypersensitivity (DTH) response to antigen-loaded autologous, dendritic cell vaccine (DC) injected intradermal in vivo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ELISpot Response to Melanoma</measure>
    <time_frame>12 mo</time_frame>
    <description>Peripheral blood CD8+ and CD4+ T cell responses against autologous tumor cells, and HLA-presented melanoma epitopes, using ELISPOT and MHC-peptide tetramer assays.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Metastatic Melanoma</condition>
  <arm_group>
    <arm_group_label>Vaccine co-cultured with melanoma cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic Cells co-cultured with melanoma cells injected as a vaccine intra/peri-nodally under ultrasound guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine pulsed with tumor cell lysates</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic Cells pulsed with tumor cell lysates were injected as a vaccine intra/peri-nodally under ultrasound guidance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccine fused with tumor cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dendritic Cells fused with tumor cells were injected as a vaccine intra/peri-nodally under ultrasound guidance</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination</intervention_name>
    <description>Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.</description>
    <arm_group_label>Vaccine co-cultured with melanoma cells</arm_group_label>
    <arm_group_label>Vaccine pulsed with tumor cell lysates</arm_group_label>
    <arm_group_label>Vaccine fused with tumor cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have Stage III-IV melanoma (any tumor thickness and any number of lymph
             node involvement, and in-transit metastases, or distant metastases) (AJCC). Each
             diagnosis will be confirmed by pathology review at the Melanoma Center of the
             University of Pittsburgh Cancer Institute.

          -  All subjects have to be HLA-A2 positive (required for immunologic testing).

          -  Subjects must have recovered fully from surgery.

          -  Availability of resectable or tissue banked tumor cells for autologous tumor dendritic
             cell vaccine preparation.

          -  Sufficient number of tumor cells available for autologous tumor dendritic cell vaccine
             preparation (min 2.6 x 10 7).

          -  Sufficient number of DCs of at least 12 X 10 6 for preparation of the autologous tumor
             dendritic cell vaccine preparation (if less than needed number of cells will be
             obtained by one course of leukopheresis, the second leukopheresis will be repeated 2
             weeks apart).

          -  Subjects must not have received any chemotherapy or immunotherapy within the four
             weeks preceding vaccination (six weeks for nitrosourea, mitomycin).

          -  Subjects must have an expected survival of greater than or equal to 12 months.

          -  Subjects must have an ECOG performance status 0 or 1.

          -  Subjects must have the following initial and subsequent pretreatment

          -  laboratory parameters: Granulocytes &gt;=2,500/mm3 Lymphocytes &gt;=1000/mm3 Platelets
             &gt;100,000/mm3 Serum Creatinine &lt;=1.5 X the ULN AST, ALT, GGT, LDH, Alk phos &lt;= 2.5 X
             the ULN Serum Bilirubin &lt;=1.5 X ULN

          -  Subjects must be &gt;= 18 years of age and must be able to understand the written
             informed consent.

          -  No evidence of active infection, regardless of the degree of severity or localization.
             Subjects with active infections (whether or not they require antibiotic therapy) may
             be eligible after complete resolution of the infection. Subjects on antibiotic therapy
             must be off antibiotics for at least 7 days before beginning treatment.

          -  Subjects with measurable disease must have an evaluation for extent of disease (tumor
             staging) performed within 30 days of start of treatment.

          -  Pretreatment baseline evaluations for laboratory parameters must be obtained within 10
             to18 days of subject registration

        Exclusion Criteria:

          -  Subjects currently treated with anti inflammatory agents including glucocorticoid
             therapy are ineligible.

          -  Subjects currently on treatment with steroids are ineligible, but may receive the DC
             autologous tumor dendritic cell vaccine 4 weeks after steroid cessation. Subjects on
             maintenance steroids because of adrenal insufficiency are eligible.

          -  Subjects with severely abnormal liver function tests [AST (SGOT), ALT (SGPT), GGT,
             Alk.Phos, LDH, and total bilirubin greater than 2 X ULN].

          -  Subjects with uncontrolled pain.

          -  Subjects with autoimmune disease, HIV, and hepatitis

          -  Subjects with symptomatic brain metastasis.

          -  Subjects with active prior malignancy (with exception of non-melanoma skin cancers and
             carcinoma in situ of the cervix).

          -  Subjects who have been previously immunized with melanoma vaccine until 10 subjects
             have been registered in each treatment arm.

          -  Subjects who are pregnant.

          -  Subjects who have sensitivity to drugs to provide local anesthesia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Kirkwood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC UPCI HCC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Upmc Upci Hcc</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <results_first_submitted>January 13, 2016</results_first_submitted>
  <results_first_submitted_qc>July 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 16, 2017</results_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>John Kirkwood</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 16 subjects were enrolled, one subject was referred to hospice and never began the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DCs Co-cultured With Melanoma Cells</title>
          <description>DCs co-cultured with melanoma cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
        <group group_id="P2">
          <title>DCs Pulsed With Tumor Cell Lysates</title>
          <description>DCs pulsed with tumor cell lysates
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
        <group group_id="P3">
          <title>DCs Fused With Tumor Cells</title>
          <description>DCs fused with tumor cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DCs Co-cultured With Melanoma Cells</title>
          <description>DCs co-cultured with melanoma cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
        <group group_id="B2">
          <title>DCs Pulsed With Tumor Cell Lysates</title>
          <description>DCs pulsed with tumor cell lysates
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
        <group group_id="B3">
          <title>DCs Fused With Tumor Cells</title>
          <description>DCs fused with tumor cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="43" upper_limit="72"/>
                    <measurement group_id="B2" value="44.5" lower_limit="32" upper_limit="59"/>
                    <measurement group_id="B3" value="54" lower_limit="49" upper_limit="81"/>
                    <measurement group_id="B4" value="49" lower_limit="32" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Delayed Type Hypersensitivity (DTH) Response</title>
        <description>Delayed type hypersensitivity (DTH) response to antigen-loaded autologous, dendritic cell vaccine (DC) injected intradermal in vivo</description>
        <time_frame>12 mo</time_frame>
        <population>Patients who met inclusion criteria and received at least 3 doses of the vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>DCs Co-cultured With Melanoma Cells</title>
            <description>DCs co-cultured with melanoma cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
          <group group_id="O2">
            <title>DCs Pulsed With Tumor Cell Lysates</title>
            <description>DCs pulsed with tumor cell lysates
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
          <group group_id="O3">
            <title>DCs Fused With Tumor Cells</title>
            <description>DCs fused with tumor cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
        </group_list>
        <measure>
          <title>Delayed Type Hypersensitivity (DTH) Response</title>
          <description>Delayed type hypersensitivity (DTH) response to antigen-loaded autologous, dendritic cell vaccine (DC) injected intradermal in vivo</description>
          <population>Patients who met inclusion criteria and received at least 3 doses of the vaccine</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ELISpot Response to Melanoma</title>
        <description>Peripheral blood CD8+ and CD4+ T cell responses against autologous tumor cells, and HLA-presented melanoma epitopes, using ELISPOT and MHC-peptide tetramer assays.</description>
        <time_frame>12 mo</time_frame>
        <population>Patients who met inclusion criteria and received at least 3 doses of the vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>DCs Co-cultured With Melanoma Cells</title>
            <description>DCs co-cultured with melanoma cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
          <group group_id="O2">
            <title>DCs Pulsed With Tumor Cell Lysates</title>
            <description>DCs pulsed with tumor cell lysates
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
          <group group_id="O3">
            <title>DCs Fused With Tumor Cells</title>
            <description>DCs fused with tumor cells
Vaccination: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Leukapheresis: All selected subjects will undergo leukapheresis. Two and a half times the subject's blood volume will be processed per procedure. A single 4 hour leukapheresis will be done.</description>
          </group>
        </group_list>
        <measure>
          <title>ELISpot Response to Melanoma</title>
          <description>Peripheral blood CD8+ and CD4+ T cell responses against autologous tumor cells, and HLA-presented melanoma epitopes, using ELISPOT and MHC-peptide tetramer assays.</description>
          <population>Patients who met inclusion criteria and received at least 3 doses of the vaccine</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were not collected/monitored per Arm/Group</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants (Overall Study)</title>
          <description>For all arms: DC vaccine Co-cultured With Melanoma Cells; DC Vaccine Pulsed With Tumor Cell Lysates; DC Vaccines Fused With Tumor Cells</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lymphatics-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>SGPT (ALT) (serum glutamic pyruvic transaminase)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor pain (onset or exacerbation of tumor pain due to treatment)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mood alteration-anxiety, agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Kirkwood, MD</name_or_title>
      <organization>University of Pittsburgh</organization>
      <phone>(412) 623-7707</phone>
      <email>KirkwoodJM@upmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

